Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stivarga
Pharma
Bayer sells cancer drug Stivarga to Grünenthal for up to $431M
Patent protection for Stivarga is expected to last until 2029 in the EU and 2030 in the U.S., but has already expired in China.
Angus Liu
Sep 21, 2026 10:20am
Fierce Biotech
Exelixis plans shuttering of East Coast site, 130 layoffs
Aug 29, 2025 9:15am
FDA signs off on Takeda's colorectal cancer drug Fruzaqla
Nov 9, 2023 10:54am
Takeda, Hutchmed hook up on cancer drug for $1.13B
Jan 23, 2023 10:31am
Servier, Taiho's Lonsurf excels in colorectal cancer upgrade
Jan 18, 2023 3:50pm
ESMO: Eyeing Bayer, Hutchmed touts 'practice-changing' CRC win
Sep 7, 2022 6:30pm
Fierce Biotech
Fierce Biotech
Fierce Biotech
Fierce Biotech
